BioPharmSignal logoBioPharmSignal

Biotech News

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

Eagle Pharmaceuticals (EGRX)Eagle PharmaceuticalsEarnings

WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three and six months ended June 30, 2025, are available at

Related news

EGRXEagle Pharmaceuticals2025-10-06 23:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2025-09-17 20:43 EST

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

View all latest news

Eagle Pharmaceuticals

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on hospital and acute-care products. Its business has historically centered on commercialization of focused injectable or hospital-based medicines.

Recent company news

EGRXEagle Pharmaceuticals2026-01-14 15:21 EST

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

EGRXEagle Pharmaceuticals2025-10-30 10:50 EST

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2025-10-21 20:05 EST

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

EGRXEagle Pharmaceuticals2025-10-15 20:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2025-10-06 23:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

Stock data

Close
0.05 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States